Multicentre cohort study of acute cholecystitis management during the COVID-19 pandemic
Purpose To analyse acute cholecystitis (AC) management during the first pandemic outbreak after the recommendations given by the surgical societies estimating: morbidity, length of hospital stay, mortality and hospital-acquired SARS-CoV-2 infection rate. Methods Multicentre-combined (retrospective–prospective) cohort study with AC patients in the Community of Madrid between 1st March and 30th May 2020. 257 AC patients were involved in 16 public hospital. Multivariant binomial logistic regression (MBLR) was applied to mortality. Results Of COVID-19 patients, 30 were diagnosed at admission and 12 patients were diagnosed during de admission or 30 days after discharge. In non-COVID-19 patients, antibiotic therapy was received in 61.3% of grade I AC and 40.6% of grade II AC. 52.4% of grade III AC were treated with percutaneous drainage (PD). Median hospital stay was 5 [3–8] days, which was higher in the non-surgical treatment group with 7.51 days (p < 0.001) and a 3.25% of mortality rate (p < 0.21). 93.3% of patients with SARS-CoV-2 infection at admission were treated with non-surgical treatment (p = 0.03), median hospital stay was 11.0 [7.5–27.5] days (p < 0.001) with a 7.5% of mortality rate (p > 0.05). In patients with hospital-acquired SARS-CoV-2 infection, 91.7% of grade I–II AC were treated with non-surgical treatment (p = 0.037), with a median hospital stay of 16 [4–21] days and a 18.2% mortality rate (p > 0.05). Hospital-acquired infection risk when hospital stay is > 7 days is OR 4.7, CI 95% (1.3–16.6), p = 0.009. COVID-19 mortality rate was 11.9%, AC severity adjusted OR 5.64 (CI 95% 1.417–22.64). In MBLR analysis, age (OR 1.15, CI 95% 1.02–1.31), SARS-CoV-2 infection (OR 14.49, CI 95% 1.33–157.81), conservative treatment failure (OR 8.2, CI 95% 1.34–50.49) and AC severity were associated with an increased odd of mortality. Conclusion In our population, during COVID-19 pandemic, there was an increase of non-surgical treatment which was accompanied by an increase of conservative treatment failure, morbidity and hospital stay length which may have led to an increased risk hospital-acquired SARS-CoV-2 infection. Age, SARS-CoV-2 infection, AC severity and conservative treatment failure were mortality risk factors..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
European journal of trauma and emergency surgery - 47(2021), 3 vom: 19. März, Seite 683-692 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Martínez Caballero, Javier [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Acute cholecystitis |
| Anmerkungen: |
© Springer-Verlag GmbH Germany, part of Springer Nature 2021 |
|---|
| doi: |
10.1007/s00068-021-01631-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR044250401 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR044250401 | ||
| 003 | DE-627 | ||
| 005 | 20230520011651.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210609s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00068-021-01631-1 |2 doi | |
| 035 | |a (DE-627)SPR044250401 | ||
| 035 | |a (SPR)s00068-021-01631-1-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.80 |2 bkl | ||
| 084 | |a 44.65 |2 bkl | ||
| 100 | 1 | |a Martínez Caballero, Javier |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multicentre cohort study of acute cholecystitis management during the COVID-19 pandemic |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Springer-Verlag GmbH Germany, part of Springer Nature 2021 | ||
| 520 | |a Purpose To analyse acute cholecystitis (AC) management during the first pandemic outbreak after the recommendations given by the surgical societies estimating: morbidity, length of hospital stay, mortality and hospital-acquired SARS-CoV-2 infection rate. Methods Multicentre-combined (retrospective–prospective) cohort study with AC patients in the Community of Madrid between 1st March and 30th May 2020. 257 AC patients were involved in 16 public hospital. Multivariant binomial logistic regression (MBLR) was applied to mortality. Results Of COVID-19 patients, 30 were diagnosed at admission and 12 patients were diagnosed during de admission or 30 days after discharge. In non-COVID-19 patients, antibiotic therapy was received in 61.3% of grade I AC and 40.6% of grade II AC. 52.4% of grade III AC were treated with percutaneous drainage (PD). Median hospital stay was 5 [3–8] days, which was higher in the non-surgical treatment group with 7.51 days (p < 0.001) and a 3.25% of mortality rate (p < 0.21). 93.3% of patients with SARS-CoV-2 infection at admission were treated with non-surgical treatment (p = 0.03), median hospital stay was 11.0 [7.5–27.5] days (p < 0.001) with a 7.5% of mortality rate (p > 0.05). In patients with hospital-acquired SARS-CoV-2 infection, 91.7% of grade I–II AC were treated with non-surgical treatment (p = 0.037), with a median hospital stay of 16 [4–21] days and a 18.2% mortality rate (p > 0.05). Hospital-acquired infection risk when hospital stay is > 7 days is OR 4.7, CI 95% (1.3–16.6), p = 0.009. COVID-19 mortality rate was 11.9%, AC severity adjusted OR 5.64 (CI 95% 1.417–22.64). In MBLR analysis, age (OR 1.15, CI 95% 1.02–1.31), SARS-CoV-2 infection (OR 14.49, CI 95% 1.33–157.81), conservative treatment failure (OR 8.2, CI 95% 1.34–50.49) and AC severity were associated with an increased odd of mortality. Conclusion In our population, during COVID-19 pandemic, there was an increase of non-surgical treatment which was accompanied by an increase of conservative treatment failure, morbidity and hospital stay length which may have led to an increased risk hospital-acquired SARS-CoV-2 infection. Age, SARS-CoV-2 infection, AC severity and conservative treatment failure were mortality risk factors. | ||
| 650 | 4 | |a Acute cholecystitis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hospital-acquired infection |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cholecystectomy |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a González González, Lucía |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez Cuéllar, Elías |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrero Herrero, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez Algar, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Vaello Jodra, Victor |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez Díaz, María Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Dziakova, Jana |e verfasserin |4 aut | |
| 700 | 1 | |a San Román Romanillos, Rosario |e verfasserin |4 aut | |
| 700 | 1 | |a Di Martino, Marcello |e verfasserin |4 aut | |
| 700 | 1 | |a de la Hoz Rodríguez, Ángela |e verfasserin |4 aut | |
| 700 | 1 | |a Galán Martín, Mónica |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez López, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a García Virosta, Mariana |e verfasserin |4 aut | |
| 700 | 1 | |a de la Fuente Bartolomé, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Pardo de Lama, María de Mar |e verfasserin |4 aut | |
| 700 | 1 | |a Gutiérrez Samaniego, María |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz Pérez, David |e verfasserin |4 aut | |
| 700 | 1 | |a Alias Jiménez, David |e verfasserin |4 aut | |
| 700 | 1 | |a de Nicolás Navas, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez Alegre, Juan José |e verfasserin |4 aut | |
| 700 | 1 | |a García-Quijada García, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Guevara-Martínez, Jenny |e verfasserin |4 aut | |
| 700 | 1 | |a Villadoniga, Arantxa |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez Fernández, Roberto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of trauma and emergency surgery |d Heidelberg : Springer Medizin, 2007 |g 47(2021), 3 vom: 19. März, Seite 683-692 |w (DE-627)SPR000520500 |w (DE-600)2276432-X |x 1863-9941 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2021 |g number:3 |g day:19 |g month:03 |g pages:683-692 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00068-021-01631-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.80 |q ASE |
| 936 | b | k | |a 44.65 |q ASE |
| 951 | |a AR | ||
| 952 | |d 47 |j 2021 |e 3 |b 19 |c 03 |h 683-692 | ||